Page last updated: 2024-09-05

varenicline and Atherogenesis

varenicline has been researched along with Atherogenesis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ejima, Y; Hisanaga, M; Kanaoka, Y; Kataoka, Y; Koga, M; Ohishi, K; Sugiyama, K; Yamauchi, A	1

Other Studies

1 other study(ies) available for varenicline and Atherogenesis

Article	Year
Varenicline promotes endothelial cell migration by lowering vascular endothelial-cadherin levels via the activated α7 nicotinic acetylcholine receptor-mitogen activated protein kinase axis. Toxicology, 2017, 09-01, Volume: 390 Topics: alpha7 Nicotinic Acetylcholine Receptor; Antigens, CD; Atherosclerosis; Cadherins; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Drug Partial Agonism; Enzyme Activation; Human Umbilical Vein Endothelial Cells; Humans; Mitogen-Activated Protein Kinases; Nicotinic Agonists; Phosphorylation; Risk Assessment; Signal Transduction; Time Factors; Varenicline	2017

Article

Year

Varenicline promotes endothelial cell migration by lowering vascular endothelial-cadherin levels via the activated α7 nicotinic acetylcholine receptor-mitogen activated protein kinase axis.

Toxicology, 2017, 09-01, Volume: 390

Topics: alpha7 Nicotinic Acetylcholine Receptor; Antigens, CD; Atherosclerosis; Cadherins; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Drug Partial Agonism; Enzyme Activation; Human Umbilical Vein Endothelial Cells; Humans; Mitogen-Activated Protein Kinases; Nicotinic Agonists; Phosphorylation; Risk Assessment; Signal Transduction; Time Factors; Varenicline

2017